QT dispersion as a marker for response to quinidine in patients with ventricular tachyarrhythmias

Annals of Noninvasive Electrocardiology

Volumn 5, Issue 1, 2000, Pages 39-44

  Kertland, Heather ^b   White, C Michael ^c   Chow, Moses S S ^c   Kluger, Jeffrey ^a,d,e  

^a Hartford Hosp Div of Cardiology   (United States)

^b Drug Information Center   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e HARTFORD HOSPITAL   (United States)

Author keywords

Efficacy; QT dispersion; Quinidine; Ventricular tachycardia

Indexed keywords

QUINIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; PRIORITY JOURNAL; QT INTERVAL; TREATMENT OUTCOME;

EID: 0034106757     PISSN: 1082720X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2000.tb00244.x     Document Type: Article

References (26)

1. 1. Antzelevitch C, Shimizu W, Yan GX, et al. Cellular basis for QT dispersion. 1998;30:168-173.
2. 2. Verduyn SC, Vos MA, Zande J, et al. Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired Torsade de Pointes arrhythmias. J Am Coll Cardiol 1997;30:1575-1584.
3. 3. Glancy JM, Garratt CJ, Woods KL, et al. QT dispersion and mortality after myocardial infarction. Lancet 1995;345:945-948.
4. 4. Day CP, McComb JM, Campbell RW. QT dispersion: An indication of arrhythmia risk in patients with long-QT intervals. Br Heart J 1990;63:342-344.
5. 5. Barr CS, Naas A, Freeman M, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-329.
6. 6. Buja G, Miorelli M, Turrini P, et al. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 1993;72:973-976.
7. 7. Darbar D, Luck J, Davidson N, et al. Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease. Br Med J 1996;312:874-879.
8. 8. De Bruyne MC, Hoes AW, Kors JA, et al. QTc Dispersion predicts cardiac mortality in the elderly: The Rotterdam Study. Circulation 1998;97:467-472.
9. 9. Lighezen DF, Ijac C, Hilbel T, et al. Differential effect of d-sotalol on QT dispersion in acute drug responders versus non-responders. J Am Coll Cardiol 1995;25:388A.
10. 10. Buser PT, Pfisterer ME, Kiowski W, et al. QTc dispersion: A powerful predictor of successful amiodarone therapy in complex ventricular postinfarct arrhythmias. Circulation 1995;92:1-276.
11. 11. Cui G, Sen L, Sager P, et al. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 1994;74: 896-900.
12. 12. Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852-858.
13. 13. Mason JW, for the Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-458.
14. 14. Jullian DG, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction. Lancet 1997; 349:667-674.
15. 15. Caims JA, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations. Lancet 1997;349:675-682.
16. 16. Ceremuzynski L, for the Polish Trial investigators. Effect of amiodarone on mortality after myocardial infarction: A double blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-1061.
17. 17. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized trials. Circulation 1990;82:1106-1116.
18. 18. Roden DM. Antiarrhythmic drugs. Chapter in JG Hardman, LE Limbird (eds.): McGraw-Hill, Goodman and Gilman's The Pharmacologic Basis of Therapeutics, Ninth Edition. NY, 1996, pp. 839-874.
19. 19. Vanoli E, Priori SG, Nakagawa H, et al. Sympathetic activation, ventricular repolarization and IKr blockade: Implications for the antifibrillatory efficacy of potassium channel blocking agents. J Am Coll Cardiol 1995;25:1609-1614.
20. 20. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: Mechanisms of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990;82:2235-2242.
21. 21. Dhein S, Muller A, Gerwin R, et al. Comparative study on the proarrhythmic effects of some antiarrhythmic agents. Circulation 1993;87:617-630.
22. 22. Wei K, Dorian P, Newman D, et al. Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus. J Am Coll Cardiol 1995;26:859-863.
23. 23. Ishida S, Nakagawa M, Fugino T, et al. Circardian variation of QT interval dispersion: correlation with heart rate variability. J Electrocardiol 1997;30:205-210.
24. 24. Waldo AL, Camm AJ, de Ruyter H, et al. Preliminary mortality results from the Survival with Oral D-Sotalol (SWORD) trial. J Am Coll Cardiol 1995;25:15A.
25. 25. Liu DW, Antzelevitch C. Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular myocytes: A weaker IKs contributes to the longer action potential of the M cell. Circ Res 1995;76:351-365.
26. 26. Zabel M, Hohnloser SH, Behrens S, et al. Differential effects of D-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. J Cardiovasc Electrophysiol 1997;8:1239-1245.